Pre-order Enquiry
Request Free Sample
Global Malignant Mesothelioma Therapeutics Market 2019-2023
SKU ID : TNV-14462810 | Publishing Date : 16-Jul-2019 | No. of pages : 125
Request Sample
Request Customization
Check Discounts
Global Malignant Mesothelioma Therapeutics Market: About this market
A malignant mesothelioma is a rare form of cancer affecting the thin tissue known as mesothelium that lines the lung, chest wall, and abdomen. The malignant mesothelioma therapeutics market analysis considers sales from both chemotherapy and other therapeutics. Our analysis also considers the sales of malignant mesothelioma therapeutics in Asia, Europe, North America, and ROW. In 2018, the chemotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing demand for chemotherapy will play a significant role in the chemotherapy segment to maintain its market position. Also, our global malignant mesothelioma therapeutics report also looks at factors such as increasing adoption of combination therapies, increasing use of asbestos for commercial purposes, and special regulatory designations. However, a long latency period of malignant mesothelioma, lack of disease-specific biomarkers in earlier stages, and development and approval of advanced devices for cancer treatment may hamper the growth of the malignant mesothelioma therapeutics industry over the forecast period.
Global Malignant Mesothelioma Therapeutics Market: Overview
Increasing the use of asbestos for commercial purposes
Exposure to asbestos is the primary risk factor for malignant mesothelioma. The significant rise in the use of asbestos in commercial purposes such as building materials, machines, and transport vehicles is causing this disease in the workers due to regular exposure. The extensive use of asbestos for commercial purpose will lead to the expansion of the global malignant mesothelioma therapeutics market at a CAGR of almost 7% during the forecast period.
Increasing awareness of malignant mesothelioma
The increasing incidence and prevalence of malignant mesothelioma across the world leading to an increasing need for awareness initiatives to diagnose and treat the disease at earlier stages. Many organizations are spreading awareness about the disease and advising workers who are regularly exposed to asbestos to undergo regular screening of malignant mesothelioma, which may prevent the disease progression to advanced stages. This increasing awareness is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global malignant mesothelioma therapeutics market during the forecast period 2019-2023, click here.
Competitive Landscape
With the presence of several major players, the global malignant mesothelioma therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading malignant mesothelioma therapeutics companies, that include Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and Pfizer Inc.
Also, the malignant mesothelioma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
A malignant mesothelioma is a rare form of cancer affecting the thin tissue known as mesothelium that lines the lung, chest wall, and abdomen. The malignant mesothelioma therapeutics market analysis considers sales from both chemotherapy and other therapeutics. Our analysis also considers the sales of malignant mesothelioma therapeutics in Asia, Europe, North America, and ROW. In 2018, the chemotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as growing demand for chemotherapy will play a significant role in the chemotherapy segment to maintain its market position. Also, our global malignant mesothelioma therapeutics report also looks at factors such as increasing adoption of combination therapies, increasing use of asbestos for commercial purposes, and special regulatory designations. However, a long latency period of malignant mesothelioma, lack of disease-specific biomarkers in earlier stages, and development and approval of advanced devices for cancer treatment may hamper the growth of the malignant mesothelioma therapeutics industry over the forecast period.
Global Malignant Mesothelioma Therapeutics Market: Overview
Increasing the use of asbestos for commercial purposes
Exposure to asbestos is the primary risk factor for malignant mesothelioma. The significant rise in the use of asbestos in commercial purposes such as building materials, machines, and transport vehicles is causing this disease in the workers due to regular exposure. The extensive use of asbestos for commercial purpose will lead to the expansion of the global malignant mesothelioma therapeutics market at a CAGR of almost 7% during the forecast period.
Increasing awareness of malignant mesothelioma
The increasing incidence and prevalence of malignant mesothelioma across the world leading to an increasing need for awareness initiatives to diagnose and treat the disease at earlier stages. Many organizations are spreading awareness about the disease and advising workers who are regularly exposed to asbestos to undergo regular screening of malignant mesothelioma, which may prevent the disease progression to advanced stages. This increasing awareness is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global malignant mesothelioma therapeutics market during the forecast period 2019-2023, click here.
Competitive Landscape
With the presence of several major players, the global malignant mesothelioma therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading malignant mesothelioma therapeutics companies, that include Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and Pfizer Inc.
Also, the malignant mesothelioma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
